Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation
University of Arkansas
Sanford Health
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Memorial Sloan Kettering Cancer Center
University of Chicago
M.D. Anderson Cancer Center
Galderma R&D
Regeneron Pharmaceuticals
University of Pittsburgh
Intensity Therapeutics, Inc.
Sarcoma Oncology Research Center, LLC
Momentum Data
University of Pittsburgh
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
University of Arizona
University of Arizona
Merck Sharp & Dohme LLC
University of Pittsburgh
University of Oxford
Federation Francophone de Cancerologie Digestive
Advaxis, Inc.
Advaxis, Inc.
UNC Lineberger Comprehensive Cancer Center
Galera Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center
Pfizer
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC
Revolution Medicines, Inc.
University of Wisconsin, Madison
University of Kentucky
Karyopharm Therapeutics Inc
Vidac Pharma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Soligenix
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Amgen
Baylor College of Medicine
The University of Texas Health Science Center at San Antonio
University of Texas Southwestern Medical Center
Organon and Co
Northwestern University
Takeda
VA Office of Research and Development